Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Inventory (2019 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Change in Inventory for 7 consecutive years, with $9.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 2036.97% year-over-year to $9.2 million, compared with a TTM value of $18.1 million through Dec 2025, up 364.18%, and an annual FY2025 reading of $18.1 million, up 364.18% over the prior year.
  • Change in Inventory was $9.2 million for Q4 2025 at Catalyst Pharmaceuticals, up from $9.1 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $9.2 million in Q4 2025 and bottomed at -$1.9 million in Q2 2024.
  • Average Change in Inventory over 5 years is $1.4 million, with a median of -$10000.0 recorded in 2022.
  • Peak annual rise in Change in Inventory hit 2121.1% in 2023, while the deepest fall reached 1241.86% in 2023.
  • Year by year, Change in Inventory stood at $920000.0 in 2021, then crashed by 135.54% to -$327000.0 in 2022, then skyrocketed by 2121.1% to $6.6 million in 2023, then tumbled by 107.2% to -$476000.0 in 2024, then surged by 2036.97% to $9.2 million in 2025.
  • Business Quant data shows Change in Inventory for CPRX at $9.2 million in Q4 2025, $9.1 million in Q3 2025, and -$455000.0 in Q2 2025.